-
公开(公告)号：KR102256277B1
公开(公告)日：2021-05-27
申请号：KR1020170086986
申请日：2017-07-10
Applicant: 동국대학교 산학협력단
Abstract: 본발명은 Rab5A 억제제를유효성분으로함유하는색소형성억제용조성물에관한것으로, 상기조성물은티로시나제의발현을억제하고, 멜라노좀의이동및 포식을감소시킬수 있으므로색소형성억제용도로유용하게이용될수 있다.
-
公开(公告)号：KR101665753B1
公开(公告)日：2016-10-12
申请号：KR1020130082051
申请日：2013-07-12
Applicant: 동국대학교 산학협력단
Abstract: 본발명은 miRNA 675 또는이의모방체(mimic)를유효성분으로포함하는멜라닌생성억제용조성물, 피부과색소성질환의예방또는치료용조성물, 및피부미백용조성물에관한것이다. 본발명에따른 miRNA 675 또는이의모방체는멜라닌세포에서티로시나제, Trp-1, Trp-2 및 MITF의발현을억제하고, 멜라닌생성과관련된신호전달체계인 CREB, ERK, AKT 및 NF-κB의인산화를억제하며, 동물모델에서티로시나제및 MITF의발현을억제하는우수한효과를가지고있어, 멜라닌생성억제용조성물, 멜라닌과잉생성에의한피부과색소성질환의예방또는치료용조성물, 및피부미백용조성물로유용하게이용될수 있다.
-
公开(公告)号：KR1020150007711A
公开(公告)日：2015-01-21
申请号：KR1020130082051
申请日：2013-07-12
Applicant: 동국대학교 산학협력단
CPC classification number: A61K48/00 , A23L33/13 , A23V2002/00 , A23V2200/318 , A61K8/606 , A61Q19/02
Abstract: 본 발명은 miRNA 675 또는 이의 모방체(mimic)를 유효성분으로 포함하는 멜라닌 생성 억제용 조성물, 피부 과색소성 질환의 예방 또는 치료용 조성물, 및 피부 미백용 조성물에 관한 것이다. 본 발명에 따른 miRNA 675 또는 이의 모방체는 멜라닌 세포에서 티로시나제, Trp-1, Trp-2 및 MITF의 발현을 억제하고, 멜라닌 생성과 관련된 신호 전달 체계인 CREB, ERK, AKT 및 NF-κB의 인산화를 억제하며, 동물 모델에서 티로시나제 및 MITF의 발현을 억제하는 우수한 효과를 가지고 있어, 멜라닌 생성 억제용 조성물, 멜라닌 과잉 생성에 의한 피부 과색소성 질환의 예방 또는 치료용 조성물, 및 피부 미백용 조성물로 유용하게 이용될 수 있다.
Abstract translation: 本发明涉及：包含miRNA675或其模拟物作为抑制黑素生成的活性成分的组合物; 用于预防或治疗色素沉着过度的皮肤病的组合物; 和用于增白皮肤的组合物。 根据本发明，miRNA675或其模拟物：抑制黑素细胞中酪氨酸酶，Trp-1，Trp-2和MITF的表达; 抑制与黑素生成相关的信号传导系统的CREB，ERK，AKT和NF-κB的磷酸化; 并且在动物模型中具有抑制酪氨酸酶和MITF表达的优异效果。 因此，包含miRNA675或其模拟物的组合物可以有利地用作抑制黑素生成的组合物，用于预防或治疗由过度黑素生成引起的色素沉着过度皮肤病的组合物和用于增白皮肤的组合物。
-
公开(公告)号：KR1020120041688A
公开(公告)日：2012-05-02
申请号：KR1020110108302
申请日：2011-10-21
Applicant: 동국대학교 산학협력단
Abstract: PURPOSE: A method for anti-aging of the skin is provided to suppress skin aging and to improve wrinkles of the skin. CONSTITUTION: A method for anti-aging of the skin is as follows. The light of a light emitting diode having wave length selected from 600-1000nm wavelength band is irradiated to the skin of a user. The wave length is selected from a group consisting of 630nm, 660nm, 830nm, and 850nm. The light of the light emitting diode is irradiated in the quantity of light having the range of 20 J/cm^2.
Abstract translation: 目的：提供皮肤抗衰老的方法，以抑制皮肤老化，改善皮肤皱纹。 构成：皮肤抗衰老的方法如下。 将具有选自600-1000nm波长带的波长的发光二极管的光照射到用户的皮肤上。 波长选自由630nm，660nm，830nm和850nm组成的组。 以20J / cm ^ 2的范围的光量照射发光二极管的光。
-
Patent Agency Ranking
-
公开(公告)号：KR100788241B1
公开(公告)日：2007-12-27
申请号：KR1020070006652
申请日：2007-01-22
Applicant: 동국대학교 산학협력단
IPC: C12Q1/00
CPC classification number: G01N33/5044 , G01N2500/00
Abstract: A method for screening a material for preventing or treating leukoplakia is provided to screen a prophylactic or a therapeutic agent of the leukoplakia in a high-throughput manner. A method for screening a material for preventing or treating leukoplakia comprises the steps of: (a) isolating epidermal cells of the leukoplakia and culturing them; (b) contacting candidate materials for preventing or treating the leukoplakia with the cultured epidermal cells; (c) measuring phosphorylation of I-kappaB, NF-kappaB, Akt or IKK from the candidate materials-contacted cells; and (d) selecting the candidate materials increasing the phosphorylation of I-kappaB, NF-kappaB, Akt or IKK.
Abstract translation: 提供筛选用于预防或治疗白斑病的材料的方法，以高通量方式筛选白斑病的预防或治疗剂。 用于筛选预防或治疗白斑病的材料的方法包括以下步骤：（a）分离白斑的表皮细胞并培养它们; （b）接触用于预防或治疗白斑的候选材料与培养的表皮细胞; （c）从候选材料接触细胞测量I-kappaB，NF-κB，Akt或IKK的磷酸化; 和（d）选择增加I-kappaB，NF-kappaB，Akt或IKK磷酸化的候选物质。
-
公开(公告)号：KR102116449B1
公开(公告)日：2020-05-29
申请号：KR1020180117046
申请日：2018-10-01
Applicant: 동국대학교 산학협력단
IPC: C12Q1/6883 , G01N33/50 , G01N33/68
-
公开(公告)号：KR1020090076536A
公开(公告)日：2009-07-13
申请号：KR1020080002544
申请日：2008-01-09
Applicant: 동국대학교 산학협력단
CPC classification number: A61K36/62 , A61K2236/35 , C11B9/00
Abstract: A Nelumbo nuficera extract having treatment effect on dermatitis is provided to promote melanogenesis, enhance tyrosinase activity and prevent and treat pigmentary disorder. A Nelumbo nuficera extract is isolated with n-hexane and have treatment effect on pigmentary disorder including vitiligo, white lentigo, depigmentation after inflammation, and photosensitive skin disorder. The Nelumbo nuficera is petals or stamens of Nelumbo nuficera. A Nelumbo nuficera extract essential oil is obtained by extracting and filtering the Nelumbo nuficera with n-hexane, evaporating at 40~60°C and removing hexane in vacuum. The essential oil comprises palmitic acid, linoleic acie, and their methyl ester. A therapeutic composition of pigmentary skin disorder comprises the essential oil of Nelumbo nuficera extract or palmitic acid methyl ester.
Abstract translation: 提供具有治疗皮肤炎症效果的奈洛卜提取物以促进黑素生成，增强酪氨酸酶活性并预防和治疗色素障碍。 用正己烷分离Nelumbo nuficera提取物，对颜色障碍具有治疗作用，包括白癜风，白色斑疹，炎症后色素沉着和感光性皮肤病。 Nelumbo nuficera是Nelumbo nuficera的花瓣或雄蕊。 通过用正己烷提取和过滤Nelumbo nuficera，在40〜60℃下蒸发，真空除去己烷，得到Nelumbo nuficera萃取精油。 精油包括棕榈酸，亚油酸和它们的甲酯。 色素性皮肤病的治疗组合物包括Nelumbo nuficera提取物或棕榈酸甲酯的精油。
-
19.发明授权봉독을 유효성분으로 포함하는 백반증 치료용 약제학적조성물 및 봉독에 의해 유도되는 색소침착의 억제제를스크리닝하는 방법 有权用于处理包含BEE VENOM的VITILIGO的组合物和用于筛选抑制剂对BEE VENOM诱导的色素的方法
公开(公告)号：KR100844886B1
公开(公告)日：2008-07-09
申请号：KR1020070003866
申请日：2007-01-12
Applicant: 동국대학교 산학협력단
CPC classification number: A61K38/1767 , C07K14/43572 , G01N33/5064 , G01N2500/10
Abstract: A pharmaceutical composition for treating vitiligo comprising bee venom and a method for screening an inhibitor of pigmentation induced by the bee venom are provided to use the bee venom for treating the vitiligo easily and screen the inhibitor of pigmentation induced by the bee venom in a high-throughput manner. A pharmaceutical composition comprises: a pharmaceutically effective amount of bee venom; and a pharmaceutically acceptable carrier. A method for screening an inhibitor of pigmentation induced by the bee venom comprises the steps of: (a) treating a cell with an inhibitor candidate material; (b) treating the cell with the bee venom; and (c) selecting the candidate material which inhibits phosphorylation of Ca^2+ or a cAMP response element binding protein(CREB) or inhibits expression level of a microphthalmia associated transcription factor(MITF). Further, the cell is a melanin cell.
Abstract translation: 提供了一种治疗白癜风的药物组合物，其中包括蜂毒和一种用于筛选由蜂毒引起的色素沉着抑制剂的方法，以便使用蜂毒剂容易地治疗白癜风，并筛选由蜂毒引起的高毒性抑制剂， 吞吐量方式。 药物组合物包含：药用有效量的蜂毒; 和药学上可接受的载体。 用于筛选由蜂毒引起的色素沉着抑制剂的方法包括以下步骤：（a）用抑制剂候选物质处理细胞; （b）用蜂毒处理细胞; 和（c）选择抑制Ca 2+或cAMP反应元件结合蛋白（CREB）磷酸化的候选物质或抑制小耳垢相关转录因子（MITF）的表达水平。 此外，细胞是黑色素细胞。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.022 seconds)
